Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor
Pharmacological Reviews · 2023-11 · 75 (6) · 1218-1232
DOI: 10.1124/pharmrev.123.000906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reviews, 2023-11. Verfasst von Yuesheng Zhang. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, School of Medicine, and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Vi…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, School of Medicine, and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, Virginia yuesheng.zhang@vcuhealth.org.
ORCID-Profile: Yuesheng Zhang
Förderung
- NCI NIH HHS
Zitieren
APA
Zhang, Y. (2023). Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacological Reviews, 75(6), 1218-1232. https://doi.org/10.1124/pharmrev.123.000906
Vancouver
Zhang Y. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacological Reviews. 2023;75(6):1218-1232. doi:10.1124/pharmrev.123.000906
BibTeX
@article{Zhang2023,
author = {Zhang, Yuesheng},
title = {Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor},
journal = {Pharmacological Reviews},
year = {2023},
volume = {75},
number = {6},
pages = {1218--1232},
doi = {10.1124/pharmrev.123.000906}
}
EUVIMED